Hereditary Angioedema Clinical Trial Pipeline Expands as 20+

robot
Abstract generation in progress

The Hereditary Angioedema (HAE) clinical trial pipeline is expanding significantly, with over 20 companies developing more than 30 therapeutic drugs. DelveInsight’s report highlights key advancements, including BioCryst’s acquisition of Astria Therapeutics and Intellia’s Phase 3 HAELO trial for NTLA-2002. Promising emerging therapies like KalVista Pharmaceuticals’ KVD900 and Pharvaris’ PHA121, both oral plasma kallikrein inhibitors, are progressing through clinical stages, aiming to offer new and convenient treatment options for HAE patients.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin